Novo Nordisk invests DKK750m in new laboratories for diabetes research in Denmark

The new Diabetes Research House will open in 2016 and accommodate 350 people

An impression of the new Diabetes Research House

Novo Nordisk is to invest DKK750m (around US$130m) in new laboratories at its R&D campus in Måløv, Denmark. Construction has begun and the new laboratory facility is expected to be ready for occupation in early 2016.

The new Diabetes Research House will accommodate approximately 350 people. During the construction phase, the project is expected to generate more than 1,000 jobs outside Novo Nordisk.

'The new lab facility will provide an environment for cutting-edge diabetes research within biotechnology and protein chemistry,' said Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer at Novo Nordisk.

'Here our researchers will be working closely together with leading scientists in Denmark and abroad on the discovery and development of new medicines for the treatment of type 1 and type 2 diabetes.'

The facility comprises two laboratory wings, a middle building with office space and an auditorium seating 450 people. The facility will occupy 16,500m2 on three storeys.

Novo Nordisk opened its R&D campus in Måløv in 1991 with about 300 employees. Today the campus accommodates more than 2,300 people. Globally, about 5,000 employees are involved in research and development activities at Novo Nordisk's units in Denmark, the US and China.

Featured Companies

Novo Nordisk Pharmatech (more information, website)